slotkoers
Andere beurzen
|
||
- CHF | - |
16/05 | Dpa-AFX Overzicht: BEDRIJVEN van 16.05.2024 - 15:15 | DP |
16/05 | Novartis overnamebod op MorphoSys overschrijdt minimum aanvaardingsdrempel | MT |
Omzet 2024 * | 48,92 mld. 44,46 mld. 45,02 mld. | Omzet 2025 * | 50,86 mld. 46,21 mld. 46,8 mld. | Marktkapitalisatie | 210 mld. 191 mld. 193 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 10,42 mld. 9,47 mld. 9,59 mld. | Nettowinst (verlies) 2025 * | 11,92 mld. 10,83 mld. 10,97 mld. | EV/omzet 2024 * | 4,54 x |
Nettoschuld 2024 * | 12,44 mld. 11,3 mld. 11,45 mld. | Nettoschuld 2025 * | 11,34 mld. 10,31 mld. 10,44 mld. | EV/omzet 2025 * | 4,35 x |
K/w-verhouding 2024 * |
20,1
x | K/w-verhouding 2025 * |
17,2
x | Werknemers | - |
Dividendrendement 2024 * |
3,51% | Dividendrendement 2025 * |
3,65% | Vrij verhandelbaar | 85,22% |
Recentste transcriptie over Novartis AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-01-05 | |
Director of Finance/CFO | 59 | 01-01-03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01-01-13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28-02-20 |
Chairman | 68 | 01-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,09% | 693 mld. | |
+29,39% | 584 mld. | |
-1,34% | 372 mld. | |
+20,34% | 332 mld. | |
+7,39% | 294 mld. | |
+14,25% | 239 mld. | |
-3,03% | 211 mld. | |
+8,49% | 168 mld. | |
-0,52% | 162 mld. |
- Beurs
- Aandelen
- Koers NOVN
- Koers